Siavash Atrchian, MD, FRCPC

Clinical Assistant Professor, Division of Radiation Oncology and Developmental Radiotherapeutics, UBC Department of Surgery, Radiation Oncologist, BC Cancer, Kelowna, BC

Dr. Siavash Atrchian is a Radiation Oncologist at BC Cancer Kelowna and a Clinical Assistant Professor in the Faculty of Medicine at the University of British Columbia. Dr. Atrchian specializes in Lung, Breast and Gastrointestinal tumor sites, with a special interest in Stereotactic Ablative Radiotherapy(SABR). He is the principal investigator and co-principal investigator of multiple current research studies. His research interests include: Deep Learning Applications in Radiation Oncology, SABR, Outcomes of Cancer Treatment and the role of Microbiome in cancer development.
https://surgery.med.ubc.ca/people/s-atrchian/

Michael Darud is the Director of Clinical Operations for BC Cancer Kelowna. Previously, he spent 20 years working as a Radiation Therapist so has a keen interest in the advancements in radiation treatment.

Houda Bahig, MDCM, PH.D.

Associate Professor, Department of Radiology, Radiation Oncology & Nuclear Medicine, Université de Montréal, Radiation Oncologist, CHUM, Montreal, QC

Dr Bahig specializes in the treatment of head and neck cancers and lung cancers, with a special interest for the development of pragmatic clinical trials evaluating new technological approaches to individualize radiotherapy. She also works on the development of algorithms using artificial intelligence to predict the response and side effects of head and neck, and thoracic radiotherapy.

Dr. Alanah Bergman, PhD, FCCPM

BSc McGill University, Physics (Hon), 1994
MSc McGill University, Medical Radiation Physics, 1997
PhD University of British Columbia, Physics (Medical Physics), 2007

Dr. Bergman is a senior medical physicist at BC Cancer - Vancouver and Fellow of the Canadian College of Physicists in Medicine. She provides physics leadership for many of the SABR trials and anatomical site initiations at her centre. She has contributed to protocols for some of the Canadian-led phase II/III trials and registries, including SABR-COMET-3, SIMPLIFY-SABR-COMET, SABR-5. Her interests currently lie with motion management for lung and liver SABR, re-irradiation scenarios, and clinical trials initiation.

Laura Dawson, MD, FASTRO

Professor, Department of Radiation Oncology, University of Toronto, Radiation Oncologist, PMH, Toronto, ON

Laura Dawson is Professor and Chair of the Department of Radiation Oncology at the University of Toronto, and a practicing radiation oncologist at the Radiation Medicine Program, Princess Margaret Cancer Centre, in Toronto. She is an internationally recognized leader in hepatobiliary cancer and in oligo-metastases. Her research has primarily focused on implementation of advanced radiation technologies (e.g. stereotactic body radiation therapy (SBRT) and image guided radiation therapy (IGRT)) to improve outcomes and to reduce the risk of toxicity of cancer patients. She has led phase I, II and more recently, phase III clinical trials of radiation therapy to treat patients with hepatocellular carcinoma and liver metastases. Dr. Dawson has published over 200 scientific papers and has mentored over 50 students from around the world. She has received numerous awards for her teaching, research and impact in oncology. She was the 2018 Canadian Association of Radiation Oncology (CARO) Gordon Richards lecturer, and she is the past Chair and past President of the American Society for Radiation Oncology (ASTRO).

Dr. Alexander Louie, MD, PhD, M.Sc., FRCPC

Dr. Louie’s academic focus is the use of comparative effectiveness research in lung, kidney and oligometastatic cancers. He has expertise in clinical trials, patient-reported outcomes, population databases, decision analyses, health economics and technological appraisals.

Benjamin Mou, MD, FRCPC

Radiation Oncologist, BC Cancer Kelowna
Clinical Associate Professor, University of British Columbia

Dr. Mou is a radiation oncologist at BC Cancer Kelowna and clinical associate professor at the University of British Columbia. He chairs the SABR and Lung Technical Sites Teams in Kelowna and is Past Chair of the BC Provincial Lung Radiation Oncology Group. He specializes in SABR for multiple body sites with clinical and research interests in thoracic, neurologic, and gastrointestinal malignancies. He serves as a site principal investigator for multiple international SABR clinical trials and is a provincial leader in BC Cancer’s SABR program. Dr. Mou is the SABR fellowship director in Kelowna and is the clinical lead for the provincial Lung and Spine SABR guidelines in BC.

Daniel Chang, MD FASTRO

Isadore Lampe Professor and Chair
Department of Radiation Oncology
University of Michigan
Ann Arbor, MI

Dr. Daniel Chang is currently the Isadore Lampe Professor and Chair of the University of Michigan Department of Radiation Oncology. He received his MD from Wayne State University in 2002 and completed his residency in Radiation Oncology at the University of Florida in Gainesville, Florida in 2007. He then joined the Department of Radiation Oncology at Stanford University from 2007-2022, having previously served as residency program director from 2012-2017 and the Vice Chair of Clinical Operations from 2017-2022 where he was also the Sue and Bob McCollum Professor in Radiation Oncology.
Dr. Chang is a nationally and internationally recognized expert in radiotherapy for GI malignancies. His primary research interest is in advanced radiotherapy techniques, primarily with stereotactic body radiotherapy (SBRT). He has led several studies investigating and establishing the efficacy and safety for SBRT for these diseases for liver and pancreatic tumors. His other research interests include normal tissue tolerances, quality of life after radiotherapy, and combining radiotherapy with targeted agents. In addition, he has a strong interest in the use of radiotherapy, particularly in combination with systemic agents, in patients with metastatic disease. Another area of interest is in health care utilization for patients with metastatic disease and using machine learning and other approaches to optimize care during the end-of-life period.

Drew Moghanaki, MD, MPH

Professor and Chief of Thoracic Oncology, Department of Radiation Oncology
Stanley Iezman and Nancy Stark Endowed Chair in Thoracic Radiation Oncology Research
David Geffen School of Medicine at UCLA
Staff Physician & Co-Director | VA Greater Los Angeles Lung Precision Oncology Program
UCLA Health | Jonsson Comprehensive Cancer Center
Los Angeles, CA

Dr. Drew Moghanaki (MD, MPH) is Professor and Chief of Thoracic Oncology in the UCLA Department of Radiation Oncology. He is co-director of the VA Greater Los Angeles Lung Precision Oncology Program and co-chair of the VALOR phase III randomized trial for operable stage I non-small cell lung cancer.

Professor Suresh Senan is a radiation oncologist at the Amsterdam University Medical Centers in The Netherlands. His research has focused on trials of systemic agents and radiation for lung malignancies, new radiotherapy techniques and study of population outcomes. He is a faculty member for thoracic malignancies at the European Society of Medical Oncology and the International Association for the Study of Lung Cancer. His group has previously hosted visiting Canadian radiation oncologists, and has ongoing collaborations with clinicians in Canada.

Prof. Shankar Siva PhD MBBS FRANZCR
Victorian Cancer Council Colebatch Fellow
Department of Radiation Oncology, Peter MacCallum Cancer Centre
Sir Peter MacCallum Department of Oncology, University of Melbourne
Melbourne, Australia

Dr Siva leads the Stereotactic Ablative Body Radiotherapy (SABR) program at PeterMac, treating > 450 SABR courses annually across 5 campuses. Under his leadership, the Peter Mac SABR service has become globally renowned for pioneering research in oligometastatic disease, lung and kidney cancers. Dr Siva is a dedicated clinical trialist. He has designed and co-ordinated 15 investigator-initiated clinical trials in the context of oligometastases, lung, kidney and prostate cancers, including 5 national/international TransTasman Radiation Oncology Group(TROG) multicentre trials. In total, he has over 300 peer- publications, including first or senior author publications in Lancet Oncology, Lancet Respiratory Medicine, Journal of Clinical Oncology, and JAMA Onc.

He serves in several international leadership roles, such as the Board of Directors of the Radiosurgery Society (RSS), the International Association for the Study of Lung Cancer (IASLC) Multidisciplinary Sciences committee, American Society of Clinical Oncology planning track and the American Society of Radiation Oncology (ASTRO) Science Council. His current career focuses on translating insights from the imaging and correlative specimens in his clinical trials into prognostic, predictive and actionable biomarkers. Dr Siva is scientific communicator on twitter@_ShankarSiva

Dr. Derek Hyde, PhD, FCCPM

Senior Medical Physicist, BC Cancer, Kelowna, BC
Adjunct Professor, Medical Physics, UBC - Okanagan

Dr. Hyde completed his PhD in imaging, focusing on the development of CBCT for neuroangiography. This work sparked an interest in IGRT and stereotactic techniques. Dr. Hyde was the physics lead for the team that established the first Canadian spine SABR program at Sunnybrook over 15 years ago. Since moving to Kelowna, he has continued to develop innovative strategies for SABR techniques as the physics lead and co-chair of the SABR group. He has contributed to provincial SABR protocols as well as the SABR-5 phase 2 clinical trial. His research interests include lung radiotherapy, radiomics, SRS, SABR, SFRT (Lattice), Adaptive Radiosurgery and 3D Gel Dosimetry.

Andrew Loblaw, BSc MD MSc FRCPC CIP FASCO

Radiation Oncologist, Clinician Scientist, Dual Professor,
Department of Radiation Oncology,
Institute of Health Policy Management & Evaluation
University of Toronto,
Toronto, ON

Dr Andrew Loblaw is a Radiation Oncologist, Clinician Scientist, and dual Professor in the Department of Radiation Oncology and the Institute of Health Policy Management & Evaluation at the University of Toronto. He’s the Site Group Co-Lead for Genitourinary Oncology at Sunnybrook.

He received a Bachelor of Science in Physics from the University of British Columbia and his Doctor of Medicine from Queen’s University. He completed his specialty training in Radiation Oncology concurrent with a Masters degree in Clinical Epidemiology to graduate from the Royal College’s Clinician Investigator Program all at the University of Toronto.

Dr Loblaw’s clinical practice and research interest focus on improving outcomes for men with prostate cancer and the healthcare system. He has a particularly interest in the design and conduct of clinical trials, the generation and dissemination of evidence-based guidelines and in image-guided radiotherapy.

Dr Loblaw is an Ontario Association of Radiation Oncology Clinician Scientist and a Senior Scientist at the Sunnybrook Research Institute. A Fellow of the American Society of Clinical Oncology (FASCO), he was previous Co-Chair of the ASCO’s Genitourinary Advisory Group and remains Co-Chair of the GU group for Cancer Care Ontario’s Program in Evidence-Based Care. He has authored over 300 peer-reviewed papers and has been awarded grant funding of over Cdn$52M.

Donna Murrell, PhD MSc MCCPM

Medical Physicist, Verspeeten Family Cancer Centre,
London Health Sciences Centre,
London, ON

Dr. Donna Murrell is a Medical Physicist and Clinician-Scientist at London Health Sciences Centre in London, Canada. She earned MSc and PhD degrees from the University of Western Ontario and is now an Assistant Professor in the Departments of Oncology and Medical Biophysics there. She leads the reirradiation group in London and is involved in international and national efforts to advance the field of reirradiation.

Arjun Sahgal, BSc, MD, FRCPC

Professor of Radiation Oncology, University of Toronto
Chief, Department of Radiation Oncology, Odette Cancer Centre
Sunnybrook Health Sciences Centre
Toronto, ON

Dr. Arjun Sahgal is an international clinical and research leader in the field of high precision stereotactic radiation to the brain and spine for both metastases and primary tumors. He currently serves as the Chief of the Department of Radiation Oncology at the University of Toronto affiliated Sunnybrook Odette Cancer Centre. After training at the University of Toronto in radiation oncology, he completed a radiosurgery fellowship at the University of California San Francisco. He has published, as lead or as a contributor, over 500 peer reviewed papers including in high impact journals like the Journal of Clinical Oncology, Lancet Oncology, and New England Journal of Medicine. He invented the 24 Gy in 2 SBRT fractions regimen for spinal metastases which was tested in his landmark international CCTG SC24 randomized trial, proving superiority over conventional palliative radiation with respect to complete pain response. He has been awarded a total of $42.5M in funding since his leadership. He has led several international research consortia, served as co-Chairperson of the AOSpine Tumour Knowledge Forum, and the President of the International Stereotactic Radiosurgery Society. His next phase of research is in the development of advanced MR in radiation therapy, MR adaptive RT for GBM, CT-adaptive radiotherapy, and he leads the CCTG SC29 trial that is a Canadian randomized trial of SBRT vs. conventional radiation for non-spine bone metastases.

Anand Swaminath MD FRCP(C)

Associate Professor, Department of Oncology, McMaster University
Scientist, Escarpment Cancer Research Institute
OARO Clinician Scientist and Radiation Oncologist
Juravinski Cancer Centre
Hamilton, ON

Dr. Swaminath is an Associate Professor, Clinician Scientist and Radiation Oncologist at the Juravinski Cancer Centre, McMaster University, Hamilton.
He received his medical degree from the University of Ottawa, finished residency training at McMaster University, and completed a clinical-research fellowship in image-guided radiotherapy/SBRT for lung and liver cancer at the Princess Margaret Cancer Centre.

His clinical and research interests are in the application of new technologies in radiation therapy, specifically SBRT for a wide variety of indications including lung, kidney, and liver cancer, both for symptom control and in the management of metastatic disease.

Dr. Swaminath is a PI or radiation lead on several local, national, and international trials evaluating SBRT in both the primary and metastatic setting. Some trial highlights include the lead on the Canadian LUSTRE randomized lung SBRT trial, and radiation lead on the CYTOSHRINK and RADSTER trials in kidney cancer, and ADVANCE trial for HCC. He has authored or co-authored more than 80 peer reviewed publications and book chapters, and has obtained several large-scale grants through CIHR and CCSRI for trials that both locally and nationally involve the evaluation of SBRT in the primary and metastatic setting.

Sarah Baker, MD

Assistant Professor,
University of British Columbia
Radiation Oncologist,
BC Cancer,
Surrey, BC

Dr. Sarah Baker is an Assistant Professor at the University of British Columbia and a radiation oncologist at BC Cancer Surrey, where she has worked since 2018. She received her MD from the University of British Columbia and completed residency training at the Cross Cancer Institute in Edmonton (University of Alberta). She completed a fellowship and PhD in stereotactic radiotherapy for lung and head and neck malignancies at Erasmus MC in Rotterdam, the Netherlands. Her clinical and research interests include the treatment of lung malignancies and oligometastases, with a focus on SABR and advanced radiotherapy technologies. Dr. Baker is the medical director of the Clinical Trials Unit at BC Cancer Surrey. She is the principal investigator of the upcoming international randomized clinical trial evaluating the potential benefit of precision radiotherapy for oligoprogressive cancer (“The STOP-2 Trial”).

Emma Dunne

Clinical Assistant Professor of Radiation Oncology,
Department of Surgery,
University of British Columbia,
Vancouver, Canada

Dr. Emma Dunne is a Clinical Assistant Professor of Radiation Oncology in the Department of Surgery, University of British Columbia, Vancouver, Canada since 2022. Dr. Dunne received her undergraduate education at University College Dublin, Ireland studying Molecular Genetics, prior to completing a PhD at the University of Bristol in the UK. She studied medicine at Barts and The Royal London Hospital, London, UK and completed her specialist Clinical Oncology training at The Royal Marsden Hospital. On completion of training Dr. Dunne proceeded to a 2-year Precision Fellowship at BC Cancer, Vancouver from 2017 - 2019 where she specialized in treating metastatic disease to the spine and liver with SBRT. Dr Dunne is a member of the Lung, GI and SBRT groups. Her research interests include SBRT specifically in the setting of primary and secondary liver malignancies, metastatic disease to the spine and pelvic re-irradiation.

Robert Olson, MD, FRCPC, MSc

Rob Olson is a Radiation Oncologist and researcher who practices in BC Cancer - Prince George, where he is also the Executive Medical Director. He is also the Division Head of Radiation Oncology and UBC. His primary research focus is on SABR in the setting of metastatic disease, and is the principal investigator on several SABR clinical trials, including SABR-5 and SABR-COMET-3.

Devin Schellenberg, BSc MD FRCPC

Clinical Associate Professor - UBC
Department Head, Radiation Oncology
BC Cancer - Surrey Centre

Dr. Devin Schellenberg completed medical school and Residency at the University of BC and University of Toronto. He went onto a Fellowship at Stanford University and has been the Department Head of Radiation Oncology at the BC Cancer Surrey Centre for the past 4 years. He chairs the Lung Radiation Oncology working group with CCTG and is a founding member of CAPRI (Canadian Pulmonary Radiotherapy Investigators Group).

He has been a leader in BC Cancer’s Stereotactic Ablative Body Radiotherapy (SABR) programs and his current research efforts focus on how radiation can alter the course of metastatic disease and (outside of cancer) whether radiation is able to treat heart arrhythmias.